• Skip to primary navigation
  • Skip to content
  • Skip to footer
Alzheimer's Clinical Trials Consortium

Alzheimer's Clinical Trials Consortium

  • Submit a Proposal
  • About Us
    • Committees
    • Units
  • Projects
  • Sites
  • News
  • Alzheimer’s Information
  • Contact Us

People

Michael Donohue, PhD

Michael Donohue, PhD

Michael Donohue, PhD

University of Southern California Alzheimer’s Therapeutic Research Institute (USC ATRI)

Dr. Donohue co-leads the Biostatistics Unit. His primary interests include modeling the long-term, multivariate evolution of Alzheimer’s Disease, and utilizing these models to inform ACTC clinical trial design. Dr. Donohue guides the unit on the use of analytic power calculations and model-based simulations to drive clinical trial design decisions regarding sample size, duration, analysis approach, and outcome measures. He helps ensure that ACTC trials are conducted with maximum statistical power and minimum participant burden. He helped develop the first Preclinical Alzheimer’s trials, and the Preclinical Alzheimer’s Cognitive Composite (PACC). Research funded by his R01 lead to a novel hierarchical Bayesian model, the Latent Time Joint Mixed-Effects Model (LTJMM). The model can simultaneously estimate long-term trajectories of several disease markers and includes a subject-specific latent time shift parameter to account for heterogeneity in disease stage.

Footer

Alzheimer's Clinical Trials Consortium
Alzheimer's Clinical Trials Consortium

ACTC is funded by a Cooperative Agreement from the National Institute on Aging, National Institutes of Health.  Cooperative Agreement number U24AG057437.

  • Submit a Proposal
  • About Us
  • Projects
  • Sites
  • Job Opportunities
  • News
  • Alzheimer’s Information
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • California Privacy Rights
ACTC Member ResourcesSubmit A Proposal

Copyright © USC ATRI 2023. All Rights Reserved.